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Abstract 
Background: Transcatheter aortic valve replacement (TAVR) is an alternative to surgical aortic valve 
replacement (SAVR) for the treatment of aortic stenosis in patients at intermediate, high, and extreme risk 
for mortality from SAVR. We examined recent trends in aortic valve replacement (AVR) in Michigan. 
Methods: The Michigan Society of Thoracic & Cardiovascular Surgeons Quality Collaborative 
(MSTCVS-QC) database was used to determine the number of SAVR and TAVR cases performed from 
January 2012 through June 2017. Patients were divided into low, intermediate, high, and extreme risk 
groups based on STS predicted risk of mortality (PROM). TAVR patients in the MSTCVS-QC database 
were also matched with those in the Transcatheter Valve Therapy Registry to determine their Heart 
Team-designated risk category. 
Results: During the study period 9,517 SAVR and 4,470 TAVR cases were performed. Total annual 
AVR volume increased by 40.0% (from 2,086 to 2,920), with a 13.3% decrease in number of SAVR 
cases (from 1,892 to 1,640) and a 560% increase in number of TAVR cases (from 194 to 1,280). Greater 
than 90% of SAVR patients had PROM≤8%. While >70% of TAVR patients had PROM≤8%, they were 
mostly designated as high or extreme risk by a Heart Team. 
Conclusions: During the study period SAVR volume gradually declined and TAVR volume dramatically 
increased. This was mostly due to a new group of patients with lower STS PROM who were designated 
as higher risk by a Heart Team due to characteristics not completely captured by the STS PROM score. 
 
Abstract Word Count: 245 
 
Introduction 
Since transcatheter aortic valve replacement (TAVR) was first approved by the U.S. Food and 
Drug Administration (FDA) in November 2011 for the treatment of severe aortic stenosis in patients not 
considered candidates for surgical aortic valve replacement (SAVR), there has been steady expansion of 
criteria for use based on data from prospective randomized clinical trials (1-5). Today, TAVR is no longer 
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who are at extreme, high, and intermediate risk for mortality and morbidity from SAVR as determined by 
a Heart Team. 
The most recent update from the Society of Thoracic Surgeons (STS) Adult Cardiac Surgical 
Database (ACSD) revealed a “meteoric” rise in TAVR volume since the database began capturing this 
procedure in 2012 (6). A previous study from the Michigan Society of Thoracic & Cardiovascular 
Surgeons Quality Collaborative (MSTCVS-QC) showed that overall SAVR volume in Michigan 
increased in the early years of TAVR implementation (7). This study builds on the previous study by 
utilizing the MSTCVS-QC database to examine more recent trends in aortic valve replacement (AVR) in 
Michigan, determine factors that influenced trends, compare patient characteristics between those 
undergoing SAVR and TAVR, and predict future trends based on known factors. 
 
Patients and Methods 
The MSTCVS-QC is a statewide database of collective su gical cases and associated 
perioperative, operative, and outcomes data entered into the STS ACSD with state-specific data fields. It 
comprises 33 sites that perform cardiac surgery, 21 of which also perform TAVR. The MSTCVS-QC 
database was used to identify patients who underwent SAVR, either with or without coronary artery 
bypass grafting (CABG), and patients who underwent TAVR from January 1, 2012 to June 30, 2017. (In 
the STS database, one can only tell if a patient underwent PCI ≤ 6 hrs or > 6 hrs prior to TAVR. 
Therefore, selecting patients who underwent TAVR automatically includes any patient who underwent 
TAVR+PCI, which would be equivalent to the SAVR+CABG patients in the study.) Patients who 
underwent SAVR+CABG were included because patients who undergo TAVR with PCI either 
concomitantly or in staged fashion would have undergone SAVR+CABG had TAVR not been available. 
The STS Short-Term Risk Calculator was used to calculate predicted risk of mortality (PROM) 
for patients undergoing SAVR and TAVR with the most recent clinical information available prior to the 
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PROM ≤ 15%), and extreme (PROM > 15%) risk groups based on the STS PROM, consistent with risk 
group stratification performed in previous clinical trials. 
Patients who underwent TAVR that were in the MSTCVS-QC database were also matched with 
patients who underwent TAVR in the Michigan TAVR database, which consists of patients entered into 
the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) Transcatheter Valve 
Therapy (TVT) Registry for the state of Michigan. The Heart Team-designated risk category for matched 
patients was obtained from the TVT Registry, and based on risk group stratification performed in the 
SURTAVI trial were stratified into intermediate, high, and extreme risk groups (5). Because the TVT 
database only contains patients in whom TAVRs were implanted commercially, not all of the TAVR 
patients in the MSTCVS-QC database (which contains patients who were enrolled in a clinical trial as 
well) had a corresponding match in the TVT Registry. 
Risk factors in the STS Short-Term Risk Calculator, as well as other risk factors not in the 
calculator that have been associated with increased operative mortality or are used by Heart Teams to add 
incremental risk when assessing patients for SAVR (8) were compared between SAVR and TAVR groups 
stratified by STS PROM or Heart Team-designated risk category. These include models for end stage 
liver disease score, prolonged 5-meter walk test, home oxygen use, bronchodilator therapy, and abnormal 
pulmonary function tests. Student’s t-test was performed for continuous variables. Chi-square test or 
Fisher’s exact test was used to compare categorical variables. 
The impact of expanded FDA approval dates on TAVR volume over time was assessed using 
interrupted time series regression analysis (Supplemental File). The effect of additional number of TAVR 
sites, cumulatively assessed at the end of each year, was also studied using this analysis. 
All statistical analysis was performed using SAS version 9.3 (SAS Institute, Cary, NC). 
 
Results 
 From January 2012 through June 2017, 60,419 cardiac surgical operations were performed in the 
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3,754 patients underwent SAVR+CABG, and 4,470 patients underwent TAVR +/- PCI (Figure 1). From 
January 2012 through December 2016, overall annual AVR volume increased by 40% (from 2,086 to 
2,920), with a 14% decrease in the number of SAVR cases (from 1,149 to 984), a 12% decrease in the 
number of SAVR+CABG cases (from 743 to 656), and a 560% increase in the number of TAVR cases 
(from 194 to 1,280). Trends in SAVR, SAVR+CABG, and TAVR +/- PCI volume are shown in Figure 2. 
 Stratification by STS PROM of patients who underwent SAVR or SAVR+CABG and the change 
over time is shown in Figure 3. There were 5,945 patients with STS PROM ≤ 3%, 2,896 patients with 3% 
< PROM ≤ 8%, 515 patients with 8% < PROM ≤ 15%, and 161 patients with PROM > 15%. The majority 
of patients had STS PROM ≤ 8% (i.e., low and intermediate risk patients). 
Stratification by Heart Team-designated risk category (Figure 4A) or by STS PROM (Figure 4B) 
of patients who underwent TAVR and the change over time is shown in Figure 4. There were 695 patients 
with STS PROM ≤ 3%, 2,508 patients with 3% < PROM ≤ 8%, 962 patients with 8% < PROM ≤ 15%, 
and 305 patients with PROM > 15%. Of the 4,470 patients who underwent TAVR that are in the 
MSTCVS-QC database, 3,740 patients were able to be matched with a patient in the STS/ACC TVT 
Registry. By Heart Team-designated risk category, 11 patients were low risk, 329 patients were 
intermediate risk, 2,000 patients were high risk, and 1,400 patients were extreme risk. 
Comparison of patient characteristics between SAVR and TAVR patients stratified by STS 
PROM is shown in Table 1 and by Heart Team-designated risk category in Table 2. When SAVR and 
TAVR patients were stratified by STS PROM and compared across low, intermediate, high, and extreme 
risk groups, patients undergoing TAVR were statistically significantly older, had more peripheral arterial 
disease, more previous PCI or CABG, more heart failure and history of arrhythmia, and more home 
oxygen use. When SAVR and TAVR patients were stratified by Heart Team-designated risk category and 
compared across intermediate, high, and extreme risk groups, patients undergoing TAVR were 
statistically significantly older and had more previous PCI or CABG. Interestingly, SAVR was more 
common in higher risk patients with renal dysfunction including dialysis, chronic or severe lung disease, 
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Interrupted time series regression analysis of the effect of FDA approval dates on TAVR volume 
showed only two out of eight dates at which there was a statistically significant change in level (logTAVR 
volume) but not slope (logTAVR volume/mo): before and after FDA approval of the Edwards SAPIEN valve for 
high risk patients which occurred in October 2012 (p<0.0001; 95% CI 1.96, 5.29) and before and after 
FDA approval of the Edwards SAPIEN XT valve for native and bioprosthetic valve disease in high and 
extreme risk patients which occurred in October 2015 (p=0.0363; 95% CI 1.10, 20.9). Analysis of 
additional number of TAVR sites on TAVR volume as assessed at the end of each calendar year showed 
only one time point – before and after 12/31/2012 when the total number of TAVR sites was 9 – at which 
where was a statistically significant change, again in level but not in slope (p=0.002; 95% CI 1.72, 5.60). 
 
Discussion 
Our observations in the state of Michigan are similar to those reported nationally by the STS 
ACSD (6). Namely, there has been a gradual decrease in number of SAVR cases performed, including 
SAVR+CABG, and there has been a dramatic rise in the number of TAVR cases. Based on the first two 
quarters of data we obtained from 2017, that trend is predicted to accelerate. When examining the change 
in SAVR volume stratified by STS PROM, although there has been a slight decrease in the number of 
high and extreme risk patients undergoing SAVR, this does not explain the rise in TAVR volume. 
When examining TAVR patients stratified into risk groups by STS PROM or Heart Team-
designated risk category, one notes disparity between the two graphs (Figure 4). During this time period 
TAVR was only commercially approved for extreme and high risk patients until August 2016. 
Interestingly, when patients were stratified by STS PROM, the majority of patients receiving TAVR were 
intermediate risk patients. Possible reasons to explain this include consideration of factors that may 
increase the risk of SAVR but are not in the STS Short-Term Risk Calculator. Several factors defined by 
the Valve Academic Research Consortium include porcelain or severely atherosclerotic aorta, frailty, 
hostile chest, or previous coronary bypass grafts closely adherent to the sternum or crossing the midline 
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underlying malignancy, or disability. These factors are all taken into consideration by the Heart Team 
when determining surgical risk and making therapy decisions. Another possible explanation is that these 
are patients not previously referred for or offered SAVR due to incremental risk factors who are now 
offered therapy with TAVR. They are not necessarily patients who would subtract from SAVR volume, 
which suggests why we have not yet seen a dramatic decrease in SAVR volume. 
When comparing how SAVR and TAVR patients differ with regards to procedural risk, the most 
consistent differences appear to be older age, history of previous PCI or CABG, and home oxygen use in 
patients undergoing TAVR. The higher proportion of TAVR patients who have history of previous PCI 
may be due to their undergoing staged or concomitant PCI for coronary artery disease (as opposed to 
undergoing SAVR+CABG). Interestingly, high and extreme risk SAVR patients also have more co-
morbidities in the areas of renal dysfunction, chronic lung disease, immunosuppression, and low albumin 
level. It is worthwhile to note that there are 12 sites in Michigan that perform SAVR but not TAVR. Of 
the nearly 14,000 aortic valve replacements performed during the study time period, approximately 11% 
were performed at sites at which TAVR is not performed. High or extreme risk patients at those sites may 
not have been able to travel to a site that performs TAVR and would have added to the morbidity of 
SAVR patients in the database. 
Since FDA approval of TAVR for intermediate risk patients in August 2016, there has been a 
notable increase in the proportion of intermediate risk patients who have received commercial TAVR 
(Figure 4A); this trend is expected to continue. FDA approval of TAVR in low risk patients with severe 
aortic stenosis is anticipated. Based on the fact that the majority of patients undergoing SAVR are low 
risk patients, we will likely continue to see a rapid increase in TAVR volume, perhaps this time 
accompanied by the beginning of a more dramatic decline in SAVR volume. Continued refinement of risk 
assessment tools to appropriately assess risk of SAVR vs. TAVR, especially in younger patients for 
whom long-term valve durability and the effect of permanent pacemaker placement are a concern, will 
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Our analysis is limited by its retrospective and observational nature and use of a large database 
that does not allow us to more closely examine data at the individual patient level. Missing data points for 
patient variables may have affected our ability to accurately detect differences between SAVR and TAVR 
patients. Furthermore, we did not examine the effect of same day admissions and the “minimalist 
approach” to TAVR on TAVR volumes (10,11). Finally, short (30 day) and long term outcomes were not 
reported following TAVR to determine whether better patient selection by Heart Teams improved 
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Table 1. Comparison of Patient Characteristics of Surgical Aortic Valve Replacement (SAVR) and 
Transcatheter Aortic Valve Replacement (TAVR) Patients Stratified by Society of Thoracic Surgeons 
Predicted Risk of Mortality (PROM) 
 PROM ≤ 3% 
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Legends: SD (Standard Deviation), BMI (Body Mass Index) ,HTN (hypertension), PAD (peripheral 
arterial disease), CVD (cerebrovascular disease), Cr (Creatinine),CAD (coronary artery disease), MI 
(myocardial infarction) ,PCI (percutaneous coronary intervention) , CABG (coronary artery bypass 
grafting), LVEF (left ventricular ejection fraction), CHF (congenstive heart failure) ,AVR (aortic 
valve replacement) 
Table 2. Comparison of Patient Characteristics of Surgical Aortic Valve Replacement (SAVR) and 























Age, mean (SD), y 75.0 (9.2) 79.4 (7.6) <0.0001 
75.5 
(10.5) 
80.5 (9.0) <0.0001 
73.3 
(11.5) 
80.6 (9.3) <0.0001 










0.1122 95 (59.0) 700 (50.0) 0.0304 
BMI, mean (SD), 
kg/m2 
30.6 (8.7) 30.3 (6.6) 0.4342 30.0 (7.3) 29.0 (9.1) 0.0123 31.7 (8.0) 28.6 (7.0) <0.0001 
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794 (39.7) <0.0001 
111 
(68.9) 
609 (43.5) <0.0001 






592 (29.7) 0.8131 42 (26.1) 444 (31.7) 0.1427 






719 (36.2) 0.4553 44 (27.3) 455 (32.6) 0.1735 






1.33 (1.01) <0.0001 
2.87 
(2.53) 
1.35 (0.98) <0.0001 
Dialysis, No. (%) 74 (2.6) 5 (1.5)  66 (12.8) 68 (3.4) <0.0001 47 (29.2) 72 (5.1) <0.0001 









887 (44.8) <0.0001 
112 
(69.6) 
724 (52.1) <0.0001 
Immunosuppression, 
No. (%) 
161 (5.6) 16 (4.9) 0.6067 60 (11.7) 162 (8.1) 0.0107 33 (20.5) 103 (7.4) <0.0001 













879 (66.1) 0.0014 






268 (33.5) <0.0001 85 (53.1) 112 (43.4) 0.0531 










<0.0001 79 (49.1) 968 (69.2) <0.0001 
Previous CABG, No. 
(%) 
279 (9.6) 70 (21.3) <0.0001 79 (15.3) 516 (25.9) <0.0001 24 (14.9) 421 (30.1) <0.0001 
LVEF, mean (SD), % 55 (12) 57 (11) 0.0020 50 (14) 54 (14) <0.0001 47 (14) 53 (14) <0.0001 













932 (66.6) <0.0001 






888 (44.5) 0.8889 83 (51.6) 638 (45.6) 0.1517 
Prior AVR, No. (%) 79 (2.7) 11 (3.3) 0.5206 25 (4.9) 119 (5.6) 0.3399 10 (6.2) 96 (6.9) 0.7577 
Liver disease, No. (%) 83 (2.9) 3 (0.9) 0.0441 12 (2.3) 69 (3.5) 0.1957 7 (4.4) 54 (3.9) 0.6717 
Severe lung disease, 
No. (%) 
293 (33.0) 26 (16.7) <0.0001 96 (62.3) 306 (37.6) <0.0001 56 (73.7) 349 (45.9) <0.0001 
Home oxygen use, No. 
(%) 
110 (3.8) 18 (5.5) 0.1382 37 (7.2) 250 (12.5) 0.0007 15 (9.3) 248 (17.7) 0.0069 
BMI < 21 kg/m2, No. 
(%) 
121 (4.2) 13 (4.0) 0.8535 36 (7.0) 131 (6.6) 0.7225 10 (6.2) 125 (8.9) 0.2453 
Albumin < 3.3 g/dL, 
No. (%) 
400 (15.0) 15 (5.1) <0.0001 
133 
(27.5) 
287 (15.5) <0.0001 73 (49.0) 260 (19.5) <0.0001 
 
Legends: SD (Standard Deviation), BMI (Body Mass Index) ,HTN (hypertension), PAD (peripheral 
arterial disease), CVD (cerebrovascular disease), Cr (Creatinine),CAD (coronary artery disease), MI 
(myocardial infarction) ,PCI (percutaneous coronary intervention) , CABG (coronary artery bypass 





Figure Legends: SAVR (surgical aortic valve replacement), CABG (coronary artery bypass 
grafting), TAVR (transcatheter aortic valve replacement), STS (Society of Thoracic Surgeons), ACC 
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Figure 1. Flow chart of patients included in the study from the Michigan Society of Thoracic & 
Cardiovascular Surgeons Quality Collaborative (MSTCVS-QC) database from January 1, 2012 to 
June 30, 2017.  
 
Figure 2. Annual aortic valve replacement volume from 2012-2016 with projected volume in 2017 
based on data from 1/1/17-6/30/17. SAVR = surgical aortic valve replacement, CABG = coronary 
artery bypass grafting, TAVR = transcatheter aortic valve replacement. 
Figure 3. Change in surgical aortic valve replacement volume stratified by Predicted Risk of 
Mortality (PROM). 
Figure 4. A) Change in transcatheter aortic valve replacement (TAVR) volume stratified by risk 
category as designated by the Heart Team in the Transcatheter Valve Therapy Registry. B) Change in 
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